Viking Therapeutics

Update in progress

VKTX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for metabolic and endocrine disorders. Its lead candidate VK2809 is an oral thyroid hormone receptor beta agonist in Phase IIb for non-alcoholic steatohepatitis and NAFLD. Other programs include VK5211 (Phase II for recovery after hip fracture), VK0612 (Phase II metabolic disorders and anemia), VK2735 (GLP-1 dual agonist in Phase 1), and VK0214 (TRβ agonist for X-linked adrenoleukodystrophy). Founded 2012, San Diego.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.11; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive